Verve Therapeutics, Inc.
Case Overview
33 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 10/28/2024 |
Status: | Status: Investigating |
Company Name: | Company Name: Verve Therapeutics, Inc. |
Court: | Court: District of Massachusetts |
Case Number: | Case Number: 1:24cv12218 |
Class Period: | Class Period: 08/09/2022 - 04/01/2024 |
Ticker: | Ticker: VERV |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of those who acquired Verve Therapeutics, Inc. (“Verve” or the “Company”) (NASDAQ: VERV) securities during the period of October 9, 2022 to April 1, 2024, inclusive (“the Class Period”). Investors have until October 28, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
According to the lawsuit, Verve made false and/or misleading statements and/or failed to disclose, among other things, that: (1) defendants did not fully disclose the circumstances under which the Heart-1 Phase 1b clinical trial (the "Heart-1 Trial") of VERVE-101 would be halted (VERVE-101 is an investigational gene editing medicine designed to be a single course treatment that permanently turns off the PCSK9 gene in the liver to reduce disease-driving low-density lipoprotein cholesterol (LDL-C)); and (2) defendants overstated the potential benefits of its proprietary lipid nanoparticle (LNP) delivery system.
According to the lawsuit, Verve made false and/or misleading statements and/or failed to disclose, among other things, that: (1) defendants did not fully disclose the circumstances under which the Heart-1 Phase 1b clinical trial (the "Heart-1 Trial") of VERVE-101 would be halted (VERVE-101 is an investigational gene editing medicine designed to be a single course treatment that permanently turns off the PCSK9 gene in the liver to reduce disease-driving low-density lipoprotein cholesterol (LDL-C)); and (2) defendants overstated the potential benefits of its proprietary lipid nanoparticle (LNP) delivery system.